Sodium phenylbutyrate

Drug Profile

Sodium phenylbutyrate

Alternative Names: Ammonaps; Buphenyl; CMK 304

Latest Information Update: 13 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ucyclyd Pharma
  • Developer CMIC; Swedish Orphan Biovitrum; Ucyclyd Pharma
  • Class Antineoplastics; Electrolytes; Phenylbutyrates; Small molecules
  • Mechanism of Action Ammonia scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperammonaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperammonaemia

Most Recent Events

  • 07 Dec 2016 Swedish Orphan Biovitrum obtains rights to distribute and market sodium phenylbutyrate in Europe, including United Kingdom, Germany, France, Italy and Spain
  • 15 Mar 2016 Biomarkers information updated
  • 07 May 2015 Hyperion Therapeutics has been acquired by Horizon Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top